Real-world study of iptacopan for PNH in Italy
Part of Blood & lymphatic clinical trials.
This study looks at how well iptacopan works in everyday medical practice for people with paroxysmal nocturnal hemoglobinuria (PNH) being treated in Italy. It gathers information from routine care to understand real-world effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of PNH.
- You are 18 years or older.
- You are being seen at an Italian clinic.
- You are taking or will start iptacopan as part of your regular medical care.
- You are not in another research study for PNH or its treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication, iptacopan, for children with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood condition. It aims to see how well the drug works in kids who have not tried anti-C5 therapy or who are switching from it.
This program gives access to the drug iptacopan for patients with serious conditions who have no other options. It is not a standard clinical trial but a special way to get the drug when all approved treatments have failed or are not suitable.
This trial tests a new drug called lanoracopan for the blood disease PNH. It aims to see if lanoracopan can safely control PNH symptoms and improve blood counts in patients who haven't responded well to other treatments.
This program gives adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood condition, access to danicopan, an investigational pill that may help improve anemia. It is for people who have been on Soliris or Ultomiris for at least 6 months and still have significant anemia.
This study looks at how well iptacopan works for people with PNH (a condition where red blood cells break down too quickly). It is for adults who have never used certain treatments or who have been on other similar medicines.
This trial tests a medicine called iptacopan for people with paroxysmal nocturnal hemoglobinuria (a rare blood disorder) or C3 glomerulopathy (a kidney disease). It aims to see if the drug is safe and effective for Korean patients.
Hear when a new Paroxysmal Nocturnal Hemoglobinuria (PNH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.